p38 mapk-in-2

p38 MAPK-IN-2 is an inhibitor of p38 kinase.

Dehydrocorydaline (13-Methylpalmatine) 是一种生物碱。它调节Bax，Bcl-2蛋白表达，激活caspase-7，caspase-8，并使PARP 失活。它能增强p38 MAPK 活化，具有抗炎、抗癌等功效。它具有强大的抗疟疾作用，并具低细胞毒性。

Amiodarone hydrochloride (Amiodarone HCl) 是一种抗心绞痛和 III 类抗心律失常药物，通过抑制钾通道和电压门控钠通道来增加心室和心房肌肉作用的持续时间，可导致心率和血管阻力降低。它通过成纤维细胞中的 ERK1 2和 p38 MAPK 信号传导诱导细胞增殖和肌成纤维细胞分化，可研究室上性和室性心律失常。

Lawsone methyl ether (2-Methoxy-1,4-naphthoquinone) 是从凤仙花和Swertia calycina 中分离出的，有抗真菌和抗菌活性。

Fumaric acid (2-Butenedioic acid) 与烟酸酶缺乏症相关，是癌症相关的内源性代谢物。

Calycosin (Cyclosin) 是一抗氧化和抗炎症活性天然产物。

Cornuside (Comuside) 是从山茱萸的果实中分离出的环烯醚萜苷，可用于炎症疾病的研究和促进血液循环。 它通过下调 MAPK 和 NF-κB 信号通路抑制肥大细胞介导的过敏反应，用于炎性过敏性疾病中的潜能。

Neochlorogenic acid (trans-5-O-Caffeoylquinic acid) 是在干果和其他植物中发现的一种多酚类天然产物，可抑制iNOS 和COX-2蛋白表达，抑制TNF-α和IL-1β产生，还抑制磷酸化的NF-κB p65和p38 MAPK 活化。

MAPK-IN-3 (Compound 4a) 是一种抗增殖剂，特别对 KYSE 30、HCT 116 和 HGC 27 具有强效抑制作用，其 IC50 分别为 0.57 μM、3.27 μM 和 2.28 μM。通过 p53 依赖机制，MAPK-IN-3 阻滞细胞周期，并通过 p53 非依赖机制诱导细胞凋亡。该化合物下调细胞周期相关蛋白（如 Cyclin D1 和 Cyclin B1）的表达，上调促凋亡蛋白（如裂解 PARP、裂解 caspase-7 和裂解 caspase-9）的表达，减少抗凋亡蛋白（如 Bcl-2）的表达，增加 KYSE 30 细胞内的 ROS 水平，并上调与 ROS 相关的 MAPK 信号通路成员（如 p-ERK、p-p38 和 p-JNK）的表达。

NF-κB MAPK-IN-2 (compound 14) 是一种高效的NF-κB和MAPK通路抑制剂。该化合物可抑制 p-p65、p-IκB、p-p38、p-JNK 以及 p-ERK 的蛋白表达，并减少 LPS 诱导的 TNF-α 和 IL-6 的释放。此外，NF-κB MAPK-IN-2 还能抑制 p65 和 c-Fos 的核移位，显示出在脓毒症研究中的潜在应用价值。

Dehydrocorydaline nitrate 是生物碱。Dehydrocorydaline 调节 Bax，Bcl-2蛋白表达，激活 caspase-7，caspase-8，并使 PARP 失活。它能增强 p38 MAPK 活化，具有抗炎、抗癌、抗疟疾等功效。

(±)14(15)-EET is a metabolite of arachidonic acid that is formed via epoxidation of arachidonic acid by cytochrome P450.[1],[2] It prevents increases in leukotriene B4, ICAM-1, and chemokine (C-C motif) ligand 1 (CCL2) induced by oxidized LDL in primary rat pulmonary artery endothelial cells (RPAECs) when used at a concentration of 1 μM.[3] (±)14(15)-EET induces dilation of preconstricted isolated canine coronary arterioles (EC50 = 0.2 pM).[4] It reduces myocardial infarct size as a percentage of the area at risk in a canine model of ischemia-reperfusion injury induced by left anterior descending coronary artery (LAD) occlusion when administered at a dose of 0.128 mg kg prior to occlusion or reperfusion.[5] Reference：[1]. Chacos, N., Falck, J.R., Wixtrom, C., et al. Novel epoxides formed during the liver cytochrome P-450 oxidation of arachidonic acid. Biochem. Biophys. Res. Commun. 104(3), 916-922 (1982).[2]. Oliw, E.H., Guengerich, F.P., and Oates, J.A. Oxygenation of arachidonic acid by hepatic monooxygenases. Isolation and metabolism of four epoxide intermediates. J. Biol. Chem. 257(7), 3771-3781 (1982).[3]. Jiang, J.-X., Zhang, S.-J., Xiong, Y.-K., et al. EETs attenuate ox-LDL-induced LTB4 production and activity by inhibiting p38 MAPK phosphorylation and 5-LO BLT1 receptor expression in rat pulmonary arterial endothelial cells. PLoS One 10(6), e0128278 (2015).[4]. Oltman, C.L., Weintraub, N.L., VanRollins, M., et al. Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation. Circ. Res. 83(9), 932-939 (1998).[5]. Nithipatikom, K., Moore, J.M., Isbell, M.A., et al. Epoxyeicosatrienoic acids in cardioprotection: Ischemic versus reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 291(2), H537-H542 (2006).

Tpl2 kinase inhibitor is an inhibitor of tumor progression locus 2 (Tpl2; IC50= 0.05 μM).1It is selective for Tpl2 over MEK, p38 MAPK, Src, MK2, and PKC (IC50s = >40, 180, >400, 110, and >400 μM, respectively). Tpl2 kinase inhibitor inhibits LPS-induced TNF-α production in isolated human monocytes and whole blood (IC50s = 0.7 and 8.5 μM, respectively). It enhances differentiation induced by calcitriol in HL-60 and U937 leukemia cells when used at a concentration of 5 μM.2Tpl2 kinase inhibitor (5 μM) inhibits the proliferation of KG-1a leukemia cells.3 1.Garvin, L.K., Green, N., Hu, Y., et al.Inhibition of Tpl2 kinase and TNF-α production with 1,7-naphthyridine-3-carbonitriles: Synthesis and structure-activity relationshipsBioor. Med. Chem. Lett.15(23)5288-5292(2005) 2.Wang, X., and Studzinski, G.P.Expression of MAP3 kinase COT1 is up-regulated by 1,25-dihydroxyvitamin D3 in parallel with activated c-jun during differentiation of human myeloid leukemia cellsJ. Steroid. Biochem. Mol. Biol.121(1-2)395-398(2010) 3.Wang, X., Gocek, E., Novik, V., et al.Inhibition of Cot1/Tlp2 oncogene in AML cells reduces ERK5 activation and up-regulates p27Kip1 concomitant with enhancement of differentiation and cell cycle arrest induced by silibinin and 1,25-dihydroxyvitamin D3Cell Cycle9(22)4542-4551(2010)

p38 MAPK inhibitor (IC50 = 0.38 μM). Inhibits the release of IL-1β and TNF-α in a peripheral blood mononuclear cell (PBMC) assay (IC50 values are 0.039 and 0.16 μM respectively). Laufer et al (2003) Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J.Med.Chem. 46 3230 PMID:12852754 |Kammerer et al (2007) Pharmacokinetics of ML3403 ({4-[5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenylethyl)-amine), a 4-pyridinylimidazole-type p38 mitogen-activated protein kinase inhibitor. Drug Metab.Dispos. 35 875 PMID:17344341

Verrucarin A (Muconomycin A) 是一种 D 型大环真菌毒素。Verrucarin A 是一种蛋白质合成 (protein synthesis) 的抑制剂，来源于Myrothecium verrucaria，可抑制白血病细胞系生长，并激活巨噬细胞 caspases、凋亡和炎症信号。Verrucarin A 能有效提高 p38 MAPK 的磷酸化，降低 ERK Akt 的磷酸化。Verrucarin A 通过 p21 和 p53 的诱导引起细胞周期调控的解除。

Olodanrigan (EMA401) 是具有口服活性、高选择性及外周受限的血管紧张素 Ⅱ 类型 2 受体(AT2R)拮抗剂。它的缓解疼痛的机制可能是：抑制增强的 AngII AT2R 诱导的 p38 和 p42 p44 MAPK 激活，进而阻碍 DRG 神经元的过度兴奋性及 DRG 神经元的萌发。它可用于研究神经性疼痛。

Triptonide (PG 492) 是从雷公藤中鉴定出的一种天然产物，是一种 Wnt 信号抑制剂，其 IC50约为 0.3 nM。它具有免疫抑制、抗炎、避育、神经保护和抗淋巴瘤作用。

Sesaminol 是从Justicia orbiculata 中分离得到的一种天然产物，抑制脂质过氧化，具有神经保护作用和抗氧化活性。它通过抑制JNK、p38 MAPKs 和caspase-3磷酸化，抑制MAPK 的级联反应。

E6201 (ER-806201) is a potent dual kinase inhibitor targeting MEK1 and FLT3, inhibiting their activities in an ATP-competitive manner. It effectively suppresses MEK1-induced ERK2 phosphorylation (IC50 = 5.2 nM), MKK4-induced JNK phosphorylation (IC50 = 91 nM), and MKK6-induced p38 MAPK phosphorylation (IC50 = 19 nM). E6201 exhibits anti-tumor and anti-psoriasis effects [1] [2].

NF-κB MAPK-IN-1 是一种有效的 NF-κB 和 MAPK 通路双重抑制剂，具有潜在的抗炎活性，抑制 NO 生成，对 LPS 诱导的iNOS，COX-2，ERΚ和P38激活有抑制作用。 NF-κB MAPK-IN-1 可用于预防和治疗类风湿关节炎 (RA) 。

AS1940477 is p38 MAPK inhibitor. AS1940477 inhibited the enzymatic activity of recombinant p38α and β isoforms but showed no effect against other 100 protein kinases including p38γ and δ isoforms. In human peripheral blood mononuclear cells, AS1940477 inhibited lipopolysaccharide (LPS)- or phytohemagglutinin A (PHA)-induced production of proinflammatory cytokines, including TNFα, IL-1β, and IL-6 at low concentrations (LPS TNFα, IC(50)=0.45n M; PHA TNFα, IC(50)=0.40 nM). In addition, equivalent concentrations of AS1940477 that inhibited cytokine production also inhibited TNFα- and IL-1 β-induced production of IL-6, PGE(2), and MMP-3 in human synovial stromal cells. AS1940477 was also found to potently inhibit TNF production in whole blood (IC(50)=12 nM) and effectively inhibited TNFα production induced by systemically administered LPS in rats at less than 0.1mg kg (ED(50)=0.053 mg kg) with an anti-inflammatory effect lasting for 20h after oral administration. Overall, this stu......

Pexmetinib (ARRY-614) 是一种口服生物可利用的双重 p38 MAPK Tie-2 抑制剂，可研究急性骨髓性白血病，并可通过 P38 STAT3 信号通路抑制破骨细胞形成和乳腺癌诱导的骨溶解。

Sauchinone 是一种从Saururus chinensis 中获得的非对映异构的木脂素。它通过抑制I-κBα磷酸化和p65核易位来抑制 LPS 诱导的 iNOS，TNF-α 和 COX-2 表达。它具有抗炎和抗氧化活性。

Semapimod是一种抑制促炎细胞因子产生的化合物，具有抑制TNF-α、IL-1β和IL-6功能。它通过抑制巨噬细胞的p38 MAPK以及一氧化氮的生成发挥作用，并且能够抑制TLR4信号传导（IC50约为0.3 μM）。Semapimod对于治疗各类炎症和自身免疫性疾病显示出潜在效用。